Why the study?
A knowledge gap exists in the pediatric heart failure population regarding appropriate pharmacotherapy and device therapies compared with adult trials.
The review emphasizes the need to address knowledge gaps in pediatric heart failure by applying pathophysiological mechanisms and lessons from adult trials.
Clinicians should exercise caution extrapolating adult HF therapies to children; leaves open the need for dedicated pediatric trials.
s focus is that the reader should specifically think through the pathophysiological mechanism of HF and the mode of action of drugs for the selection of appropriate pharmacotherapy. We review the drug and device trials in adults with HF to highlight the knowledge gap that exists in the pediatric HF population.
No takes yet. Share an insight, caveat, or question.
Das et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: